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Perinatal infection increases the vulnerability of the neonatal brain to hypoxic-ischaemic (HI) 1 
injury. Hypothermia Treatment (HT) does not provide neuroprotection after pre-insult 2 
inflammatory sensitisation by lipopolysaccharide (LPS), a gram-negative bacterial wall 3 
constituent. However, early-onset sepsis in term babies is caused by gram-positive species 4 
in more than 90 % of cases, and neuro-inflammatory responses triggered through the gram-5 
negative route (toll-like receptor 4; TLR-4), are different from those induced through the 6 
gram-positive route via TLR-2. Whether gram-positive septicaemia sensitises the neonatal 7 
brain to hypoxia and inhibits the neuroprotective effect of HT is unknown. 8 
Seven-day-old (P7) Wistar rats (n=178) were subjected to intraperitoneal injections of 9 
PAM3CSK4 (1 mg/kg, a synthetic TLR-2 agonist) or vehicle (0.9% NaCl). After an 8-hour 10 
delay, the left carotid artery was ligated followed by 50min of hypoxia (8% O2) at Trectal36°C. 11 
Pups received 5h treatment of normothermia (NT, 37°C) or HT (32°C) immediately after the 12 
insult. Brains were harvested after seven days’ survival for hemispheric and hippocampal 13 
area loss analyses and immunolabelling of microglia (Iba1) and hippocampal neurons 14 
(NeuN). Normothermic PAM3CSK4-animals showed significantly more brain injury than 15 
vehicle animals (p=0.014). Compared to NT, HT significantly reduced injury in the 16 
PAM3CSK4-injected animals, with reduced area loss (p<0.001), reduced microglial activation 17 
(p=0.006), and increased neuronal rescue in the CA1 region (p<0.001).  Experimental 18 
induction of a sepsis-like condition through the gram-positive pathway sensitises the brain to 19 
HI. HT was highly neuroprotective after the PAM3CSK4-triggered injury, suggesting HT may 20 
be neuroprotective in the presence of a gram-positive infection. These results are in strong 21 
contrast to LPS-studies where HT is not neuroprotective.22 
  3 
Introduction 1 
 2 
Perinatal hypoxic-ischaemic (HI) brain injury remains one of the major causes of long-term 3 
neurological disability or death in term newborns [1]. Perinatal infection is a risk factor for 4 
cerebral palsy (CP) and long-term disability [2–4], and systemic inflammation also lowers the 5 
threshold at which an HI insult leads to permanent neuronal injury [5–7]. Several small and 6 
large animal studies have demonstrated the infection-induced vulnerability of the brain to 7 
hypoxia, and investigated the mechanisms behind [8–11]. Interestingly, a generalised 8 
systemic inflammatory activation seems to be sufficient to cause this sensitisation, even in 9 
the absence of the pathogen itself. Chau et al showed that meningitis is not a prerequisite to 10 
increase susceptibility of the brain to HI, and most clinical studies linking severity of brain 11 
injury to perinatal infection have instead examined pro-inflammatory cytokines or clinical 12 
signs of perinatal infection, such as maternal pyrexia or clinical chorioamnionitis [3,12]. 13 
Furthermore, the success rate of pathogen isolation from the blood of neonates with clinical 14 
infection is poor at only 6% [13]. Pre-clinical animal models of simulated infection in the 15 
setting of HI injury often use inflammatory triggers like lipopolysaccharide (LPS), a 16 
constituent of gram-negative bacterial membrane, in place of the complete bacteria 17 
[8,9,14,15]. Systemic activation of immune cells will not only induce an inflammatory cascade 18 
in peripheral blood, but also induces inflammatory activation in brain tissue. The elevated 19 
cytokines and activated microglia elicit what is referred to as the infection-sensitised 20 
immature brain [7,15,17].  21 
For term neonates with moderate and severe hypoxic-ischaemic encephalopathy (HIE) as a 22 
result of HI brain injury, hypothermia treatment (HT) is standard of care, and our only current 23 
treatment option [18]. With a number needed to treat of 8, 45-50% of encephalopathic term 24 
babies will still die or have long-term disability despite active HT therapy [19]. Based on a 25 
diverse range of clinical and pre-clinical studies, doubt exists as to whether HT is 26 
neuroprotective in infants with HIE where perinatal infection is a co-morbidity [6,20,21]. We 27 
recently showed experimentally that HT is not neuroprotective after pre-insult inflammatory 28 
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sensitisation with LPS in a post-natal day 7 (P7) rat model of unilateral HI brain injury [8]. 1 
LPS triggers the immune system primarily by binding to toll-like receoptor (TLR) 4, but is 2 
likely to only represent infections caused by gram-negative bacteria which contain LPS in 3 
their cell wall [22]. However in term neonates in developed countries where HT is standard of 4 
care, culture positive sepsis has been shown to be caused by gram-positive bacterial species 5 
in >90 % of cases [13]. Peptidoglycans and lipoteichoic acid on the wall of gram-positive 6 
bacteria trigger human immune responses by binding to TLR-2, and thereby induce a 7 
different pathway to inflammatory activation [23–25]. We previously investigated the neuro-8 
inflammatory responses in neonatal rat pups receiving systemic LPS, compared to those 9 
receiving the synthetic TLR-2 agonist PAM3CSK4 (PAM). Profound differences in temporal 10 
core temperature development, as well as in brain cytokine expression and inflammatory and 11 
apoptotic signal molecules were found, in response to the two different types of systemic 12 
inflammation [26]. 13 
Whether gram-positive septicaemia sensitises the neonatal brain to HI the way gram-14 
negative septicaemia does, and whether it abolishes the neuroprotective effect of HT (as 15 
seen in LPS sensitization), is not known.  16 
We therefore investigated the sensitising effect of systemic TLR-2 activation on the neonatal 17 
rat brain, as a model of gram-positive systemic inflammation in the setting of HI brain injury, 18 
in the P7 rat. Additionally we investigated whether HT is neuroprotective in this double-hit 19 
setting.  20 
21 
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Materials and methods 1 
Animals and injections 2 
All experiments were approved by the University of Oslo's Animal Ethics Research 3 
Committee and performed by individuals holding an approved license according to the 4 
Animal (Scientific Procedures) Act of 1986. Experiments were performed on 7-day-old 5 
(P7) Wistar rats (Charles River Laboratories, Sulzfeld, Germany) of both sexes. All pups 6 
were kept in an animal facility with a 12h:12h-hour dark:light cycle at 19-21°C 7 
environmental temperature with food and water ad libitum.  8 
To trigger inflammation through the TLR-2 pathway we used a synthetically-9 
manufactured TLR-2 agonist (N-palmitoyl-S(2,3-bis(palmitoyloxy)-(2R,S-propyl)-®-10 
cysteinyl-seryl-(lysyl)3-lysine, PAM3CSK4 or PAM, Vaccigrade, Sigma-Aldrich) at a dose of 1 11 
mg/kg body weight. PAM was initially dissolved in sterile LPS-free water, and then diluted in 12 
sterile physiologic saline (0.9% NaCl). The dose of PAM was based on previous 13 
publications on this agonist used in neonatal rodents [27–29], in combination with our 14 
own dose-response experiments (data not shown). Control groups received a single dose 15 
of sterile saline vehicle. All injections were given intraperitoneally (i.p.) in a volume of 10 µl/g 16 
body weight.  17 
Animals were randomised across litter, sex and weights before the experiments commenced, 18 
to one of the following treatment groups; vehicle injection (Veh) and normothermia treatment 19 
(NT) (Veh-NT), PAM injection and NT (PAM-NT), Veh injection and hypothermia treatment 20 
(HT) (Veh-HT), and PAM injection and hypothermia treatment (PAM-HT).  21 
 22 
Surgical Procedures 23 
All experiments were performed as previously described for the LPS-sensitised modification 24 
of the Vannucci model of unilateral HI [8]. Briefly, at the start of each experiment, animals 25 
were injected with PAM or Veh according to randomisation. After an 8-hour delay with their 26 
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dams, pups were exposed to a mild HI insult (ligation of left carotid artery under isoflurane 1 
anaesthesia followed by exposure to 8% O2 for 50 min). Immediately thereafter, pups 2 
received either of the 2 allocated treatments: 5 h of NT (Trectal 37.0°C) or HT (Trectal 32.0°C). 3 
During treatment, the core and surface temperature of two ‘sentinel' pups from the Veh 4 
groups, was continuously recorded in each chamber. Rectal temperature was maintained 5 
within ±0.2°C of the target value using a continuous temperature recording (IT-21; Physitemp 6 
Instruments, Clifton, N.J., USA), which servo-controlled a water-filled mat (CritiCool, MTRE, 7 
Yavne, Israel) on the floor of the chamber. 8 
After the 5 h treatment period, pups were returned to their dams. Pups were sacrificed on 9 
postnatal day (P) 14 for further analyses.  10 
 11 
Histopathology and Area loss analyses 12 
At P14, animals were sacrificed by trans-cardiac perfusion-fixation with 10% neutral-13 
buffered formalin under isofluraneN2O-anaesthesia. Brains were harvested and kept in 14 
10% neutral-buffered formalin until further processing. Three mm coronal blocks were 15 
cut using a standard rat matrix (ASI instruments Inc., Warren, MI, USA), and embedded 16 
in paraffin. Five µm slices were cut from the two neighboring blocks best representing 17 
cortex, hippocampus, basal ganglia and thalamus. These were stained with hematoxylin 18 
and eosin (H&E) and scanned (Epson Perfection V750 Pro). Virtual slides were exported 19 
with 600 dpi resolution. Optical density and hemispheric area was analysed using 20 
ImageJ computer software (ImageJ, version 1.46r, National Institutes of Health, 21 
Bethesda, MD, USA). The ligated side was compared to the non-ligated side, and area 22 
loss of the ligated side calculated by the formula (1 – (area left/area right))*100. Percent 23 
hemispheric area loss at this level has previously been shown to be highly correlated with a 24 
formal neuropathology score and global degree of injury in this model [30]. 25 
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Evaluation of hippocampal area loss was performed in the same way, and calculated as: 1 
(1 − (area of left hippocampus/area of right hippocampus))*100. A subset of the H&E stained 2 
sections were examined for hemispheric and hippocampal areas by two blinded assessors to 3 
check for inter-rater reliability. 4 
 5 
Immunohistochemistry 6 
For immunohistochemistry analysis, slides were prepared from paraffin-embedded 7 
sections as for H&E staining. Antigen retrieval was then performed in citrate buffer 8 
solution at pH 6.0, using a PT link instrument (Dako, Glostrup, Denmark). After blocking 9 
with 10% goat serum, primary rabbit antibody against Iba1 (1:1,000; WAKO), or mouse 10 
antibody against NeuN (1:500; Millipore), was applied overnight at 4°C. In control brain 11 
sections, the primary antibodies were omitted. After rinsing with PBS, the slices were 12 
incubated for 1 h at room temperature with secondary Alexa Fluor 568 and/or 488 13 
(Invitrogen, 1:500) antibodies. Finally, the slides were rinsed and coverslipped with 14 
ProLong Gold with DAPI (Invitrogen). Sections were scanned with a virtual microscopy 15 
scanner (Axio Scan.Z1; Carl Zeiss, Jena, Germany) using the fluorescence mode with 16 
plan apochromatic 20X lens. Virtual slides were exported as high-resolution tiff images 17 
for further analysis. 18 
To evaluate the effect of different treatments on neuronal loss, NeuN and DAPI-positive 19 
cells in the CA1 region of the hippocampus were counted, as this region is known to be 20 
particularly vulnerable to hypoxia at P7 [31,32]. Aiming for a representative subset from 21 
each treatment group, the 10 animals closest to the median hemispheric area loss, were 22 
selected for formal hippocampal neuron counting.Three non-overlapping fields of the CA1 23 
region in the left hippocampi were assessed. Counting was performed by two individual 24 
observers blinded to the treatment group, and an average of the two was taken. The 25 
total number of neurons across the three fields of each hippocampus was summed and 26 
compared across groups. 27 
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To investigate inflammatory activation, staining for ionised calcium-binding adapter 1 
molecule 1 (Iba1, a microglial specific biomarker) was performed. Iba1 positive cells were 2 
separated from background and analysed by ImageJ. The summed colour intensity 3 
detected was calculated as a L/R hemispheric ratio and normalised to cross-sectional 4 
area before comparison across groups. The results from two blinded assessors were 5 
compared by calculating their correlation coefficient to validate the method. 6 
 7 
Data Analysis 8 
Statistical analyses were performed using GraphPad Prism version 6 (GraphPad Software 9 
Inc., La Jolla, Ca, USA) and SPSS software version 22 (SPSS Inc., Chicago, IL, USA). As 10 
data were not normally distributed, the Kruskal-Wallis test was used for four-group treatment 11 
comparison, and Mann-Whitney U-test was used for two-group comparisons to get exact 12 
two-tailed p-values. Graphical data are presented as median with 95% confidence intervals 13 
(CI). A p-value of <0.05 was considered statistically significant.  14 
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Results 1 
Mortality and exclusions 2 
Of the 218 pups initially included no mortality was seen from injections alone. Four pups died 3 
during experimental surgical procedures and hypoxia. Pups carrying temperature probes in 4 
each experiment were excluded from further analysis (n=16), because the stress of carrying 5 
the probe could influence the outcome [33]. A total of 198 pups were therefore included in 6 
analysis. 20 pups served as juvenile controls, without receiving an injection. 7 
 8 
Hemispheric Area loss after Systemic injections without HI  9 
To make sure a systemic inflammation triggered by injection of PAM does not create brain 10 
tissue loss on its own, P7 rat pups received injections according to the above mentioned 11 
protocol with Veh (n=22) or PAM (n=23). Juvenile control (JC) animals of equivalent age 12 
(n=20) were used as controls. Total cross sectional area was compared across groups, as 13 
well as right hemispheric area and left hemispheric area separately. There was no statistical 14 
difference between treatment groups in any of the analyses (Kruskal-Wallis test; p=0.4, 0.5 15 
and 0.3 respectively) (data not shown).  16 
 17 
Hypothermic neuroprotection in PAM sensitised HI injury  18 
In the NT treated groups, animals receiving a single i.p. injection of PAM prior to the HI 19 
insult were more vulnerable to 50 minutes of hypoxia and had significantly increased 20 
hemispheric area loss (35.8%, CI 20.4-48.6) compared to Veh-injected pups (10.4%, CI 21 
2.1-37) (p=0.01). Treating PAM-injected pups with HT reduced median area loss (6.6%, 22 
CI 4.4-18.8), and thereby showed a significant neuroprotective effect compared to PAM 23 
animals treated with NT treatment (p=0.0002) (Figure 1).   24 
Also hippocampal area loss was significantly higher in PAM-NT pups (55.5%, CI 26.3-25 
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69.2) compared to Veh-NT (13.4%, CI 3.1-40.2) (p=0.03). Significant hypothermic 1 
neuroprotection in the hippocampal region was seen in PAM-HT animals (8.2%, CI 3.6-2 
18.2) (p=0.003) (Figure 2). In the cortical area loss analyses we found the same 3 
differences, with PAM-NT pups having significantly more cortical tissue loss (50.4%, CI 4 
25.1-67.6) compared to the Veh-NT group (18.5%, CI 2.4-54.2) (p = 0.03). Significant 5 
neuroprotection in the cortical region was seen in PAM-HT animals (8.2%, CI 3.6-18.2) 6 
(p=0.003). Thalamic area loss was not significantly increased in the PAM-sensitised 7 
pups (28.8%, CI 13.2-46.3) compared to Veh-NT animals (14.2%, CI 7-32.1). There was, 8 
however, significant neuroprotective effect on thalamic tissue in the PAM-HT group 9 
(9.3%, CI 3.2-18) (p=0.01). 10 
There was no statistical difference between Veh-injected pups treated with NT and Veh-11 
animals receiving HT treatment, neither with respect to hemispheric (10.4%, CI 2.1-37 12 
vs 10.9%, CI 7.2-15.4) area loss, nor to hippocampal (13.4%, CI 3.1-40.2 vs 7.6% CI 13 
0.5-29.4), cortical (18.5%, CI 2.4-54.2 vs 15.9%, CI 9.8-20.5) or thalamic (14.2%, CI 7-14 
32.1 vs 9.3%, CI 4.5-12.6) area loss.  15 
Linear regression analysis showed a highly significant correlation between area loss in 16 
all three regions and hemispheric area loss (Hippocampus: R2=0.77, p<0.0001; Cortex: 17 
R2=0.89, p<0.0001; Thalmus: R2=0.78, p<0.0001), with hippocampal and cortical loss 18 
tending to be greater (B=1.32 and B=1.27 respectively) than hemispheric area loss, while 19 
thalamic loss is slightly lower (B=0.92) (Figure 3). This is in accordance with regional 20 
analysis of vulnerability in the Vannucci rat model when exposed to HI only [31]. 21 
 22 
Hypothermia Provides Neuronal Rescue in the CA1 Hippocampal Region. 23 
The total number of neurons in the CA1 region of the left hippocampus were counted in 24 
a subset of animals from all 4 treatment groups (n=10-11 per group) (Figure 4). The 25 
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number of neurons after a short HI insult was significantly lower in PAM-NT animals (44, 1 
CI 0-103) compared to Veh animals (122, CI 73-135) (p=0.01). Significant neuronal 2 
rescue was seen in the PAM-HT group (107, CI 94-141) (p=0.0008). There was no 3 
difference between the two Veh-injected groups (NT: 121.8, CI 73-135 vs HT: 114, CI 4 
99.5-128). 5 
 6 
PAM induced microglial activation 7 
Iba1 upregulation was more pronounced, and greater relative to the amount of remaining 8 
tissue, in PAM-NT animals (p=0.035). Microglial activation was reversed in the PAM-HT 9 
group, with significantly reduced Iba1 immunolabelling (p=0.006) (Figure 5). Microglial 10 
activation, with bigger somas and retracted dendritic processes, was morphologically 11 
visible around the left hemispheric lesions of all animals (Figure 6). 12 
 13 
Discussion 14 
This study investigated the sensitising effect of systemic TLR-2 activation on the immature 15 
rat brain, combined with a mild unilateral HI insult. The motivation was to improve our pre-16 
clinical model of infection-senistised HI brain injury to more closely resemble the clinical 17 
situation in term asphyxiated neonates, where gram-positive infections predominate. Here 18 
we provide evidence that PAM, a TLR-2 agonist, does sensitise the immature brain when 19 
injected systemically. Importantly, PAM injected animals are equally vulnerable to HI as 20 
those sensitised by LPS [8]. However, HT still provides >80% neuroprotection of hemispheric 21 
area loss in animals administered PAM. This is in stark contrast to studies on LPS-induced 22 
sensitisation, where HT was ineffective.  23 
Analyses of hippocampal area loss and neuron count in the CA1 region gave similar 24 
neuroprotection of HT after sensitisation with PAM. In the PAM groups, treatment with HT 25 
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resulted in an 85% reduction of total hippocampal tissue loss, and 2.4-fold higher number of 1 
surviving neurons in the CA1 region of the hippocampus. Tissue loss in the cortex followed 2 
the same pattern across the groups, with again significant neuroprotection in PAM-HT 3 
animals. Interestingly, thalamus is a less vulnerable area to the sensitizing effect of PAM, 4 
without worse outcome in the PAM-NT group compared to Veh-NT. Still hypothermia 5 
reduces injury significantly also in this region. Additionally, microglial activation relative to 6 
cross-sectional area was increased in PAM-sensitised brains. This was reversed by HT, with 7 
a 55% reduction of Iba1 expression.  8 
 9 
Injection of PAM or of LPS, alone results in neuro-inflammatory alterations that differ highly 10 
depending on the inflammatory stimulus [34]. Our own experiments have shown that LPS-11 
injected rat pups become hypothermic soon after injection, with a spontaneous core 12 
temperature drop of 3.5°C, from 35°C down to 31.5°C [26]. This decrease in core 13 
temperature was not seen in animals injected with PAM, which were not different from Veh 14 
animals. Intra-hypoxic temperature is known to have large impact on the susceptibility of the 15 
neonatal rat brain to HI injury [35]. At higher core temperatures during hypoxia, neonatal rats 16 
are more susceptible to brain injury, and vice versa, at lower body temperature it is more 17 
challenging to create a lesion [36]. The drop in core temperature we have seen after LPS 18 
injection, which is still present when the experiment commences, might partly be the reason 19 
for their increased vulnerability compared to Veh animals [5]. In studies on LPS-sensitisation 20 
the rats receive the insult at the same intra-hypoxic temperature as control groups (36ºC) 21 
[5,8], meaning their temperature during hypoxia is rapidly increased by 4.5°C when placed in 22 
the hypoxia chamber. The temperature of Veh pups or juvenile control animals on the other 23 
hand, is only increased by up to 1°C during the hypoxia period. This does, however, not 24 
explain why PAM injected pups, which maintain the same core temperature as Veh animals 25 
post-injection, present a vulnerability to hypoxia similar to that of LPS-injected pups. This 26 
suggests that other mechanisms are as important as temperature when it comes to the 27 
brain’s resistance to an HI insult.  28 
  13 
HI brain injury without systemic inflammation induces a lowering of core temperature [35,37]. 1 
During hypoxia there is also reduced metabolism and heat production [38]. The detailed 2 
mechanism behind this phenomenon, however, is not fully understood, and an innate 3 
neuroprotective defense mechanism has been suggested [35]. Experimental HI brain injury 4 
without infectious pre-sensitisation, is where HT has repeatedly been shown to be 5 
neuroprotective [39]. We therefore speculate whether the reduced core temperature found 6 
after injection of LPS might be more of a pathologic response, with disturbance of the 7 
thermoregulatory center in hypothalamus. Linthorst et al. have demonstrated several 8 
disturbances in the thalamic preoptic area after i.p. LPS administration, which substantiates 9 
this theory [40]. These changes have to not been investigated after PAM sensitisation. A 10 
study comparing these responses after PAM or LPS would help elucidate these mechanisms 11 
and their influence in infection-sensitised brain injury.  12 
 13 
Resting microglia are activated in response to HI injury [41–43]. Studies on LPS-sensitised 14 
HI injury have demonstrated microglia to be both more numerous and in a more activated 15 
state around the site of the lesion [17,44,45]. The sensitising effect of LPS on the immature 16 
brain has been attributed to the number of activated microglia. Here we demonstrate a 17 
similar microglial response after PAM, with comparable increased neuronal vulnerability. This 18 
could suggest that microglial activation and proliferation is involved in the pathogenic 19 
inflammatory activation and brain sensitisation due to the combination of PAM and HI. It is 20 
however noteworthy that both area loss and microglial activation after PAM-sensitised HI is 21 
largely reversed by HT, while this is not the case after LPS. Microglial activation seems to be 22 
non-specific to the pathogen, and part of a more distal common pathway of neuro-23 
inflammatory responses. In both models, the increased microglial response in sensitised 24 
brains is associated with a higher median degree of neuronal injury, due to the “double hit” 25 
insult, compared to controls. A constituent tonic inhibition of microglial activity occurs through 26 
ligand-receptor pairs from neurons, requiring direct cell-cell contact [43]. Even in the absence 27 
of damage-related signals, loss of neuronal integrity can induce a rapid microglial response 28 
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[46]. The upregulation of Iba1 could therefore represent a response to a more 1 
comprehensive injury, which occurred prior to the microglial activation. As these microglia 2 
are stained after 7 days’ survival, and are not phenotyped, their activation state is likely to be 3 
towards what was previously defined as the M2 phenotype on the classification spectrum, 4 
and a sign of inflammatory repair mechanisms [47]. The dramatic difference in sensitivity to 5 
HT indicates that other, earlier, inflammatory events are more important in the mechanistic 6 
explanation of inflammatory pre-sensitisation to neuronal Hi injury. 7 
 8 
A limitation to this study is the lack of significant HT neuroprotection in the Veh-injected 9 
animals. We do however see a somewhat lower median hippocampal area loss in the Veh-10 
HT group compared to the Veh-NT group, although not statistically significant. This goes well 11 
with how the hippocampus has been shown to be the most sensitive area to HI, but also the 12 
most sensitive to HT neuroprotection [48]. The lack of difference in hemispheric area loss 13 
may be due to the low degree of injury in this cohort as a result of the short hypoxia period 14 
(50 minutes compared to 90 minutes in our standard HI injury model without presensitisation) 15 
[30,49]. In our experience HT has not been neuroprotective after mild brain injury, defined in 16 
the Vannucci model as a median area loss below 25% [50,51]. A moderate degree of injury 17 
(30-60% tissue loss) is required to see neuroprotective effect of HT in this model [30,52]. 18 
Whether mild injury should be eligible for cooling in neonates is still debated, as the 19 
neuroprotective effect of HT has not been clarified for these patients [53]. Rat pups are highly 20 
variable in how much hypoxia they can withstand before cellular death is seen, and the same 21 
is likely to be the case for human neonates. The well-described variability of injury in the 22 
Vannucci model demands a substantial sample size, and the careful use of non-parametric 23 
statistical approaches. However, this model has been an important part of translating 24 
therapeutic hypothermia from bench to bedside [54], and harboring such variability might be 25 
part of what makes the model translatable. When we modify the model to include systemic 26 
infectious inflammatory activation, chances are high that processes and pathways are 27 
induced that still remain to be uncovered. The immune system is far from fully-mapped, and 28 
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furthermore, studies on translation of immune responses across species are scarce [55]. 1 
 2 
Though the focus of research on pre-sensitisation has primarily been based around bacterial 3 
infections, general signs of infection are mostly non-specific, and could be associated with 4 
other infectious agents. Some of the studies associating severity of brain injury to systemic 5 
inflammation used maternal fever as a sign of infection [2,3], but, the most common cause of 6 
fever is viral infections including influenza, rhinovirus, enterovirus and coronavirus [56]. The 7 
pre-sensitising effect of viral-induced materno-fetal inflammation has not been well 8 
investigated clinically. A study by Stridh et al on neonatal mice demonstrated significantly 9 
increased infarct volume after pre-sensitisation with an agonist to TLR-3, the pathogen 10 
recognition receptor of viral RNA [57]. Fever is induced by raised circulating levels of certain 11 
cytokines, specifically IL-6 [58], which occurs during both bacterial and viral illnesses [59]. A 12 
well-known consequence of intrapartum maternal infection is the fetal inflammatory response 13 
syndrome (FIRS), also characterised by elevated IL-6 levels in the fetus [60]. Whether this is 14 
dependent on the pathogen is not known, and could indeed include maternal viral infections 15 
as well as bacterial chorioamnionitis. With respect to how viral infections may interact with 16 
HT treatment in asphyxiated neonates, it is interesting to note that infections with common 17 
cold viruses increase in the winter season, and cold viruses have been shown to replicate 18 
better at cold environmental temperatures like in the nasal cavity (33-35°C) than at normal 19 
core temperature (37°C). The mechanism behind this is not yet elucidated, but is thought to 20 
be due to diminished antiviral immune responses at these lowered temperatures [61]. 21 
Cooling neonates with a viral infection might therefore bring them to a temperature that 22 
promotes the growth of certain virsues. The downstream effects of that are unknown. 23 
 24 
Eklind et al. developed a modification of the Vannucci model with systemic inflammation 25 
to pre-sensitise the brain to HI [5]. They used lipopolysaccharide (LPS) as a systemic 26 
inflammatory trigger, and thereby modelled a gram-negative bacterial infection. This 27 
finding was particularly important with respect to the prematurely born population [62,63], 28 
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and furthermore to populations of less developed parts of the world, where the incidence 1 
of gram-negative infections is higher, and HT was [64]. Our group found the same HI-2 
sensitising effect of LPS on the brain, however we showed that HT neuroprotection was 3 
negated in LPS-sensitised rat pups using that model [8,17]. Studies on HT in low-income 4 
settings have not been able to find neuroprotective effect [20], and HT is to date 5 
standard of care only in western high-income countries. On this basis, and knowing our 6 
target patient group to mostly have infections caused by gram-positive bacteria, we 7 
further-developed a model of gram positive infection, using a synthetic TLR-2 antagonist, 8 
as described. Activation of TLR-2 triggers inflammatory activation through the same 9 
pathway that initiates sepsis from gram positive species [25,65]. Surprisingly, and in 10 
opposition to the results seen in the LPS model, we demonstrate a neuroprotective effect of 11 
HT. This might not uncover the whole story, but it does underline the importance of tailoring 12 
our pre-clinical models as thoroughly as we can to the clinical scenario we aim to mimic.  13 
 14 
With these data we can only conclude that HT treatment can be highly neuroprotective in 15 
inflammatory pre-sensitised HI injury, but the neuroprotective effect might depend on the 16 
pathogen. With current knowledge, our results in combination with clinical infection 17 
demographics suggests that we should continue to treat encephalopathic neonates who fulfill 18 
the cooling criteria, regardless of infectious status. 19 
20 
  17 
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Figures legends 1 
 2 
 3 
Figure 1. Hemispheric area loss (%). 4 
Bars show median with 95% confidence interval. Postnatal day 7 (P7) rat pups were injected 5 
intraperiotoneally with vehicle (Veh) or PAM3CSK4 (PAM). After an 8-hour-delay all pups had 6 
their left carotid artery ligated before 50 minutes of 8% hypoxia. Pups were randomized to 5 7 
hours of normothermia treatment (NT) (37°C) or hypothermia treatment (HT) (32°C), with 7 8 
days’ survival. PAM injected animals treated with NT (PAM-NT) had significantly more injury 9 
compared to the Veh-NT group. HT provided significant neuroprotection in PAM-injected 10 
group (PAM-HT). *p=0.01, ***p=0.0002. 11 
 12 
Figure 2. Hippocampal area loss (%).  13 
Bars show median with 95% confidence interval. PAM3CSK4-injected (PAM) pups receiving 14 
normothermia treatment (NT) (PAM-NT) lost significantly more hippocampal tissue than 15 
vehicle-injected pups (Veh-NT) receiving the same treatment. Hypothermia treatment (HT) 16 
was significantly neuroprotective in PAM-injected pups (PAM-HT) *p=0.03, **p=0.003.  17 
 18 
Figure 3. Correlation between regional and hemispheric area loss. 19 
Symbols represent unique animals, with lines denoting the correlation between hemispheric 20 
area loss and area loss in hippocampus (circles) (R2=0.77), thalamus (squares) (R2=0.78) or 21 
cortex (triangles) (R2=0.89). 22 
 23 
Figure 4. Hippocampal neuroncount.  24 
Symbols represent the number of hippocampal neurons in the hippocampal CA1 region of 25 
each animal. Lines show the median. The neuroncount was significantly lower in PAM3CSK4-26 
injected (PAM) animals compared to vehicle-injected (Veh) animals in the normothermia (NT) 27 
  26 
groups. Hypothermia (HT) provides significant neuronal rescue after PAM sensitization. 1 
*p=0.01, **p=0.008 (A).  2 
Representative images from the hippocampal CA1 region are shown from each experimental 3 
group (B). 4 
 5 
Figure 5. Iba1 density (microglial activation) relative to cross-sectional brain area. 6 
PAM3CSK4-injected (PAM) animals treated with normothermia (NT) (PAM-NT) have a greater 7 
degree of microglial activation relative to remaining tissue, compared to vehicle-injected 8 
(Veh) pups receiving the same treatment (Veh-NT).  9 
Hypothermia treatment (HT) counteracts this effect. *p=0.035, **p=0.006. 10 
 11 
Figure 6. Representative images of microglia stained for Iba 1. 12 
Above: A vehicle-injected (Veh) normothermia treated (NT) (Veh-NT) animal showing 13 
ramified resting microglia with a small soma and long slender branched processes. Below: A 14 
PAM3CSK4-injected (PAM-NT) animal demonstrating proliferation and upregulation of 15 
activated microglia, with big round soma and retracted processes.  16 
